Tlando (testosterone) Capsule
3
Pharmacology Brochure Discussion
Elizabeh Jusu
Chamberlin University College of Nursing
Nursing
Lisa South
9th December, 2021
Pharmacology Brochure Discussion
This brochure introduces a recent medication that was approved by the FDA but has not been in the market for long. It is a source of quick information but covers most of the essential areas of information that a nurse would need to have on their fingertips concerning the drug. Dayvigo is a sleeping pill that was approved in 2019, and whose effectiveness is quite high (FDA 2020). The drug is a lemborexant of the sedative-hypnotics class. It is an oral tablet whose dosage should not exceed 10mg. When co-administered with a CYP3A inhibitor, the dosage should be kept at only 5mg (Drugs.com, 2021). It is an effective medication for treating insomnia but can have serious side effects so it is essential for nurses to be well aware of its use, contraindications, side effects and other potential issues that could arise from its use.
References
Drugs.com. (2021). Lemborexant. Day ago. Full Drug Information. https://www.drugs.com/mtm/lemborexant.html
Food and Drgug Administration (2020). Drug Approval Package- Dayvigo. https://www.google.com/search?q=DAyvigo+FDa&oq=DAyvigo+FDa&aqs=chrome..69i57j35i39l2j0i512l4j69i60.3636j1j7&sourceid=chrome&ie=UTF-8